AXA 41.520 € (+0,24 %) SOITEC 159.950 € (+4,95 %) 
ING GROEP N.V. 29.630 € (+0,70 %) HERMES INTL 1 283.000 € (+1,62 %) LVMH 380.000 € (-0,24 %) TOOSLA 0.000 € (-33,33 %) BE SEMICONDUCTOR 179.450 € (-0,25 %) CRCAM TOURAINE CCI 112.000 € (+2,56 %) 
DSM FIRMENICH AG 100.650 € (+2,81 %) LECTRA 20.850 € (+1,96 %) EUTELSAT COMMUNIC. 1.380 € (-1,85 %) AIRBUS 187.800 € (+0,29 %) CHRISTIAN DIOR 413.000 € (-0,48 %) ASR NEDERLAND 71.480 € (+0,22 %) SAFRAN 316.200 € (+1,74 %) ABIVAX 79.000 € (+2,46 %) 2CRSI 24.800 € (+5,80 %) VEOLIA ENVIRON. 31.090 € (+0,65 %) AUBAY 49.700 € (+2,47 %) ASML HOLDING 1 601.600 € (-1,78 %) MEDINCELL 29.060 € (+16,89 %) TIKEHAU CAPITAL 16.000 € (+2,70 %) ENGIE 22.750 € (+0,18 %) VOPAK 51.100 € (-0,10 %) RIBER 8.100 € (-3,46 %) UMG 14.900 € (+1,50 %) ABN AMRO BANK N.V. 40.450 € (+1,51 %) ALSTOM 15.600 € (-1,14 %) MAGNUM 15.358 € (-0,60 %) FASTNED 43.450 € (+2,36 %) TOTALENERGIES 78.530 € (+1,22 %) INFOTEL 38.000 € (+2,15 %) PHILIPS KON 21.780 € (+1,40 %) ADP 103.700 € (+1,57 %) PERRIER (GERARD) 72.200 € (+0,28 %) 
UNILEVER 55.300 € (+1,24 %) SHELL PLC 45.035 € (+0,64 %) EURONEXT 163.600 € (+1,18 %) ELIS 21.260 € (+0,76 %) ADUX 1.000 € (-1,96 %) MERCIALYS 9.460 € (0,00 %) ADYEN 886.100 € (+2,84 %) BOUYGUES 40.300 € (-0,81 %) 
ARCELORMITTAL SA 57.280 € (+5,64 %) FONCIERE INEA 31.100 € (+0,32 %) BOLLORE 3.668 € (+0,55 %) WOLTERS KLUWER 75.000 € (+4,49 %) CEGEDIM 10.700 € (-0,56 %) TELEPERFORMANCE 71.800 € (+2,63 %) GL EVENTS 24.300 € (+2,75 %) SERGEFERRARI GROUP 5.540 € (-0,36 %) SCHNEIDER ELECTRIC 266.400 € (+2,03 %) BIOMERIEUX 83.200 € (+3,48 %) ASM INTERNATIONAL 883.600 € (-1,65 %) EMEIS 10.050 € (+1,67 %) CLARIANE 3.322 € (+2,72 %) GROUPE SFPI 1.730 € (-0,57 %) HIGH CO 3.485 € (+1,90 %) REXEL 34.110 € (+2,34 %) LUMIBIRD 22.500 € (+2,74 %) |
16/09/2026 07:30
Inside Information / Other news releasesSensorion Announces Confidential Submission of Draft Registration Statement to the SEC for Potential U.S. Initial Public OfferingMontpellier (France) and Cambridge, MA (United States); September 16, 2026, 7:30am CET – Sensorion (FR001401A9Z0 – ALSEN) (“the Company”) a pioneering clinical-stage biotechnology company focused on developing novel therapies to restore hearing and treat and prevent hearing loss disorders, announced today that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the “SEC”). The confidential submission is a preliminary step in the Company's evaluation of a potential U.S. initial public offering of its ordinary shares, including in the form of American Depositary Shares (“ADSs”), and the listing of such ADSs on a U.S. national exchange, subject to market and other conditions. This press release does not, and is not intended to, constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933. About SensorionSensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. ContactsInvestor Relations Press Relations Label: SENSORION NotesSource : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière